WO2004007676A3 - Therapie combinee servant a traiter des tumeurs - Google Patents

Therapie combinee servant a traiter des tumeurs Download PDF

Info

Publication number
WO2004007676A3
WO2004007676A3 PCT/US2003/021783 US0321783W WO2004007676A3 WO 2004007676 A3 WO2004007676 A3 WO 2004007676A3 US 0321783 W US0321783 W US 0321783W WO 2004007676 A3 WO2004007676 A3 WO 2004007676A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasms
treatment
combination therapy
neoplasm
patient
Prior art date
Application number
PCT/US2003/021783
Other languages
English (en)
Other versions
WO2004007676A2 (fr
Inventor
Margaret S Lee
Curtis Keith
Benjamin A Auspitz
Grant R Zimmermann
M James Nichols
Original Assignee
Combinatorx Inc
Margaret S Lee
Curtis Keith
Benjamin A Auspitz
Grant R Zimmermann
M James Nichols
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc, Margaret S Lee, Curtis Keith, Benjamin A Auspitz, Grant R Zimmermann, M James Nichols filed Critical Combinatorx Inc
Priority to AU2003251875A priority Critical patent/AU2003251875A1/en
Publication of WO2004007676A2 publication Critical patent/WO2004007676A2/fr
Publication of WO2004007676A3 publication Critical patent/WO2004007676A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé servant à traiter un patient atteint d'un cancer ou d'un autre type de tumeur, ce qui consiste à administrer à ce patient (i) ciplopirox ou des analogues structuraux ou fonctionnels de ce dernier et, éventuellement, (ii) un agent antiprolifératif simultanément ou à deux semaines d'écart, en quantités suffisantes pour inhiber la croissance de la tumeur.
PCT/US2003/021783 2002-07-15 2003-07-14 Therapie combinee servant a traiter des tumeurs WO2004007676A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003251875A AU2003251875A1 (en) 2002-07-15 2003-07-14 Combination therapy for the treatment of neoplasms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39612002P 2002-07-15 2002-07-15
US60/396,120 2002-07-15
US40090502P 2002-08-02 2002-08-02
US60/400,905 2002-08-02

Publications (2)

Publication Number Publication Date
WO2004007676A2 WO2004007676A2 (fr) 2004-01-22
WO2004007676A3 true WO2004007676A3 (fr) 2004-04-08

Family

ID=30118565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021783 WO2004007676A2 (fr) 2002-07-15 2003-07-14 Therapie combinee servant a traiter des tumeurs

Country Status (2)

Country Link
AU (1) AU2003251875A1 (fr)
WO (1) WO2004007676A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101682890B1 (ko) 2008-06-30 2016-12-06 산요 시키소 가부시키가이샤 컬러필터용 안료분산체

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018014A2 (fr) * 2001-08-23 2003-03-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes d'inhibition de la formation de canaux vasculaires et procedes d'inhibition de la proliferation
AU2004298761A1 (en) * 2003-12-19 2005-06-30 Novartis Ag Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
WO2010048712A1 (fr) * 2008-10-31 2010-05-06 University Health Network Ciclopirox et cytarabine pour le traitement de troubles leucémiques
US20130178503A1 (en) * 2010-06-01 2013-07-11 Biotheryx Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
EP2576513A1 (fr) 2010-06-01 2013-04-10 Biotheryx Inc. Dérivés d'hydroxypyridone, compositions pharmaceutiques réalisées à partir de ces dérivés, et utilisations thérapeutiques correspondants pour traiter des maladies prolifératives
IT1405078B1 (it) * 2010-06-23 2013-12-16 Quattrone Composti per il trattamento di tumori che portano oncoproteine myc deregolate
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
WO2016077346A1 (fr) 2014-11-11 2016-05-19 The University Of Kansas Procédés de traitement du cancer de la vessie avec le ciclopirox, le ciclopirox olamine ou un promédicament à base de ciclopirox
CA2969540C (fr) 2014-12-02 2023-03-21 Ignyta, Inc. Combinaisons pour le traitement du neuroblastome
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
IL271759B2 (en) 2017-07-19 2024-01-01 Ignyta Inc Pharmaceutical preparations that include anthraxtinib
WO2019077506A1 (fr) 2017-10-17 2019-04-25 Ignyta, Inc. Compositions pharmaceutiques et formes galéniques solides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756118A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
US6277892B1 (en) * 1991-10-16 2001-08-21 Schering-Plough Healthcare Products, Inc. Enhanced skin penetration system for improved topical delivery of drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756118A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US6277892B1 (en) * 1991-10-16 2001-08-21 Schering-Plough Healthcare Products, Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101682890B1 (ko) 2008-06-30 2016-12-06 산요 시키소 가부시키가이샤 컬러필터용 안료분산체

Also Published As

Publication number Publication date
AU2003251875A1 (en) 2004-02-02
AU2003251875A8 (en) 2004-02-02
WO2004007676A2 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2004006906A3 (fr) Methodes de traitement de neoplasmes
WO2004006842A3 (fr) Association de medicaments pour le traitement de tumeurs
WO2005027842A3 (fr) Associations de medicaments destinees au traitement de tumeurs
WO2001066103A3 (fr) Formulation et methode de traitement des neoplasmes par inhalation
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1039887A4 (fr) Procede de traitement de neuro et nephro-toxicites et de toxicites therapeutiques par des composes d'aminothiol
WO2000040235A3 (fr) Traitement de l'asthme a l'aide d'inhibiteurs de mek
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
WO2003030823A3 (fr) Combinaisons permettant le traitement des troubles inflammatoires
WO2004007676A3 (fr) Therapie combinee servant a traiter des tumeurs
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
WO2005011572A3 (fr) Combinaison de medicaments pour le traitement des neoplasmes
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
WO2004110151A8 (fr) Traitement du cancer au moyen de composes de vitamine d actifs associes a des agents et a des traitements radiotherapeutiques
WO2004006849A3 (fr) Combinaisons de medicaments pour le traitement de neoplasmes
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2002076393A3 (fr) Agents antiangionenes, antitumoraux, et chimiopreventifs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP